Takeda Pharmaceutical (NYSE:TAK) Issues FY 2024 Earnings Guidance

Takeda Pharmaceutical (NYSE:TAK) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 3.060-3.060 for the period. The company issued revenue guidance of $30.1 billion-$30.1 billion.

Takeda Pharmaceutical Trading Up 0.1 %

Shares of NYSE TAK traded up $0.02 during midday trading on Friday, reaching $13.96. The stock had a trading volume of 811,765 shares, compared to its average volume of 1,648,926. Takeda Pharmaceutical has a twelve month low of $12.57 and a twelve month high of $15.08. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.74 and a current ratio of 1.26. The company’s 50 day moving average price is $14.47 and its 200 day moving average price is $13.79. The firm has a market cap of $44.42 billion, a price-to-earnings ratio of 24.07, a price-to-earnings-growth ratio of 0.26 and a beta of 0.54.

Takeda Pharmaceutical (NYSE:TAK) last announced its earnings results on Wednesday, July 31st. The company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.37 by $0.19. The company had revenue of $7.75 billion for the quarter. Takeda Pharmaceutical had a return on equity of 9.88% and a net margin of 6.49%. As a group, sell-side analysts expect that Takeda Pharmaceutical will post 1.58 EPS for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.